Literature DB >> 27435325

Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma.

Jung Hee Kim1, Dong Hyun Sinn2, Kyunga Kim3, Wonseok Kang1, Geum-Youn Gwak1, Yong-Han Paik1, Moon Seok Choi1, Joon Hyeok Lee1, Kwang Cheol Koh1, Seung Woon Paik1.   

Abstract

BACKGROUND AND AIMS: We evaluated the impact of primary variceal bleeding prophylaxis on long-term outcomes of patients newly diagnosed with hepatocellular carcinoma (HCC).
METHODS: A retrospective cohort of 898 patients newly diagnosed with HCC without a history of variceal bleeding [age 57.4 ± 10.4, males 718 (80.0 %)] were analyzed for new onset variceal bleeding during follow-up.
RESULTS: Variceal bleeding occurred in 72 patients (8.0 %) during follow-up. The presence of portal vein thrombosis [hazard ratio (HR) 3.90; 95 % confidence interval (CI) 2.09-7.30; p < 0.001] and the presence of the red color sign or ≥grade 2 varices at index endoscopy (HR 7.64; 95 % CI 4.56-12.80; p < 0.001) were independent risk factors for variceal bleeding. The occurrence of variceal bleeding was an independent risk factor for mortality (HR 1.39; 95 % CI 1.06-1.82; p = 0.015). The cumulative incidence rate of variceal bleeding at 1 year was 2.1, 15.3, and 34.2 % for those non-indicated for primary prophylaxis (n = 760), indicated for primary prophylaxis and received prophylaxis (n = 98), and indicated for primary prophylaxis but did not received prophylaxis (n = 40) (p < 0.001). Primary prophylaxis for variceal bleeding for indicated patients was associated with a reduced risk of mortality in all patients (HR 0.54; 95 % CI 0.33-0.88; p = 0.014) and in propensity-matched patients (HR, 0.54; 95 % CI 0.31-0.95; p = 0.033).
CONCLUSION: Variceal bleeding was independent risk factor for survival of newly diagnosed HCC patients. Screening and providing primary prophylaxis for indicated patients should be considered for patients with HCC.

Entities:  

Keywords:  Bleeding; Hepatocellular carcinoma; Prevention; Survival; Varix

Mesh:

Substances:

Year:  2016        PMID: 27435325     DOI: 10.1007/s10620-016-4255-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding.

Authors:  Brian H Lang; Ronnie T Poon; Sheung T Fan; John Wong
Journal:  Am J Gastroenterol       Date:  2004-11       Impact factor: 10.864

Review 2.  Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials.

Authors:  Lise L Gluud; Sarah Klingenberg; Dimitrinka Nikolova; Christian Gluud
Journal:  Am J Gastroenterol       Date:  2007-12       Impact factor: 10.864

3.  Endoscopic injection sclerotherapy for esophageal varices prolonged survival of patients with hepatocellular carcinoma complicating liver cirrhosis.

Authors:  R Iwakiri; T Koyama; M Hirano; Y Uchida; S Ishibashi; A Kuwahara; K Matsunaga; H Sakata; K Fujimoto
Journal:  Gastrointest Endosc       Date:  2000-05       Impact factor: 9.427

4.  Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.

Authors:  Thomas Sersté; Christian Melot; Claire Francoz; François Durand; Pierre-Emmanuel Rautou; Dominique Valla; Richard Moreau; Didier Lebrec
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study.

Authors:  Cristina Ripoll; Joan Genescà; Isis K Araujo; Isabel Graupera; Salvador Augustin; Marta Tejedor; Isabel Cirera; Carles Aracil; Margarita Sala; Manuel Hernandez-Guerra; Elba Llop; Angels Escorsell; Maria Vega Catalina; Nuria Cañete; Agustin Albillos; Càndid Villanueva; Juan G Abraldes; Rafael Bañares; Jaime Bosch
Journal:  Hepatology       Date:  2013-10-15       Impact factor: 17.425

6.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Authors:  Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-08       Impact factor: 11.382

7.  What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma?

Authors:  Kaori Kadouchi; Kazuhide Higuchi; Masatsugu Shiba; Hirotoshi Okazaki; Kazuki Yamamori; Eiji Sasaki; Kazunari Tominaga; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Tetsuo Arakawa
Journal:  J Gastroenterol Hepatol       Date:  2007-02       Impact factor: 4.029

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

9.  Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.

Authors:  Dong Hyun Sinn; Ju-Yeon Cho; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

10.  Predictors of In-Hospital Mortality in patients with hepatocellular carcinoma and Acute Variceal bleeding.

Authors:  Moataz Hassanien; Mohamed Darwish El-Talkawy; Maged El-Ghannam; Ahmed El Ray; Abdel Aziz Ali; Hoda Abu Taleb
Journal:  Electron Physician       Date:  2015-10-19
View more
  5 in total

1.  Balloon Retrograde Transvenous Obliteration for Treatment of Persistent Gastric Variceal Bleed in Patient With Hepatocellular Carcinoma.

Authors:  Jaimy Villavicencio Kim; Ismail Elkhattib; Daniela Guerrero Vinsard
Journal:  Cureus       Date:  2020-06-24

2.  The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma.

Authors:  Wei-Yao Hsieh; Ping-Hsien Chen; I-Yen Lin; Chien-Wei Su; Yee- Chao; Teh-Ia Huo; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin; Jaw-Ching Wu
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

Review 3.  Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?

Authors:  Thomas Reiberger; Theresa Bucsics; Rafael Paternostro; Nikolaus Pfisterer; Florian Riedl; Mattias Mandorfer
Journal:  Curr Hepatol Rep       Date:  2018-11-07

4.  Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.

Authors:  Jihye Lim; Ha Il Kim; Eunju Kim; Jiyoon Kim; Jihyun An; Seheon Chang; Seon-Ok Kim; Han Chu Lee; Yung Sang Lee; Ju Hyun Shim
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

5.  Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices.

Authors:  Ziwen Tao; Yuying Ruan; Zhi Peng; Kai Zhang; Yanjing Gao
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.